Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 62-year-old man with recently diagnosed heart failure with reduced ejection fraction (LVEF 30%) comes to the clinic for a follow-up visit. He is currently asymptomatic at rest but experiences dyspnea with moderate exertion. His current medications include carvedilol and dapagliflozin. The physician decides to optimize his guideline-directed medical therapy by initiating sacubitril-valsartan and spironolactone. Baseline laboratory studies show a serum creatinine of 1.1 mg/dL and a serum potassium of 4.2 mEq/L. Which of the following are necessary and appropriate ongoing monitoring and treatment evaluation strategies for this patient? (Select all that apply)

  1. Assessment of serum potassium and creatinine within 1 to 2 weeks of initiating the new medicationsCevap
  2. Utilization of N-terminal pro-B-type natriuretic peptide (NT-proBNP) rather than B-type natriuretic peptide (BNP) for future biomarker evaluationCevap
  3. C
    Monitoring of serial B-type natriuretic peptide (BNP) levels every 3 months to evaluate the therapeutic response to sacubitril-valsartan
  4. D
    Administration of an angiotensin-converting enzyme (ACE) inhibitor concurrently with the new regimen for a 36-hour transition period
  5. E
    Routine evaluation of left ventricular function using transesophageal echocardiography (TEE) every 6 months

Cevap

The appropriate strategies include assessing serum potassium and creatinine within 1 to 2 weeks of initiation, and utilizing NT-proBNP rather than BNP for future biomarker evaluation.
Guideline-directed medical therapy for heart failure with reduced ejection fraction requires careful monitoring. Initiating an angiotensin receptor-neprilysin inhibitor (ARNI) and a mineralocorticoid receptor antagonist (MRA) increases the risk of hyperkalemia and renal insufficiency, necessitating a basic metabolic panel 1 to 2 weeks after initiation. Additionally, because the neprilysin inhibitor (sacubitril) prevents the degradation of B-type natriuretic peptide (BNP), BNP levels will be elevated regardless of the patient's volume status. Therefore, N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is not degraded by neprilysin, must be used to evaluate therapeutic response.

Adım Adım Çözüm

1
Evaluate the mechanism and adverse effect profile of the newly initiated medications (sacubitril-valsartan and spironolactone).
Both medications can cause renal dysfunction and hyperkalemia. Furthermore, sacubitril inhibits the degradation of BNP.
Understanding the pharmacologic effects informs the necessary clinical and laboratory monitoring parameters.
2
Determine the optimal timeline for assessing renal function and electrolytes.
Serum potassium and creatinine should be evaluated 1 to 2 weeks after initiation.
This captures early changes in renal hemodynamics and potassium excretion, preventing severe hyperkalemia or acute kidney injury.
3
Identify the correct biomarker for ongoing evaluation of heart failure status in a patient taking an ARNI.
NT-proBNP must be used instead of BNP.
Because sacubitril directly elevates BNP levels, NT-proBNP is the only reliable natriuretic peptide marker in these patients.

Anahtar Kavram

Monitoring requirements for patients on guideline-directed medical therapy for heart failure include early assessment of renal function and potassium when initiating MRAs or ARNIs, and switching to NT-proBNP for biomarker monitoring because ARNIs falsely elevate BNP.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru